Free Trial
NASDAQ:IRD

Opus Genetics Q4 2024 Earnings Report

Opus Genetics logo
$4.08 +0.05 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.03 -0.05 (-1.32%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Opus Genetics EPS Results

Actual EPS
-$1.27
Consensus EPS
-$0.34
Beat/Miss
Missed by -$0.93
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$3.40 million
Expected Revenue
$11.10 million
Beat/Miss
Missed by -$7.70 million
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Opus Genetics' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Opus Genetics Earnings Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile